Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NASVAC
- Development stage
- Phase 3
- Lead developer
- Center for Genetic Engineering and Biotechnology
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal, Subcutaneous
01
Overview
NASVAC is a therapeutic vaccine developed for the treatment of chronic hepatitis B (CHB). It is a 1:1 formulation containing 100 μg of hepatitis B surface antigen (HBsAg) derived from Pichia pastoris recombinant HBsAg subtype adw2 and 100 μg of hepatitis B core antigen (HBcAg) purified from Escherichia coli-expressed recombinant full-length HBcAg, both sourced from a genotype-A-infected patient. The vaccine is administered through both intranasal and subcutaneous routes, and does not include adjuvants or preservatives. NASVAC has demonstrated superior efficacy compared to pegylated interferon (Peg-IFN) in reducing viral load in treatment-naïve patients with chronic HBV infection, with a better safety profile. Clinical trials have shown that NASVAC can induce anti-HBs antibodies and reduce HBsAg levels in both patients receiving nucleos(t)ide analogue treatment and asymptomatic HBV carriers.
- Brand names
- HeberNasvac
- Other names
- HeberNasvacNASVACAnti-HBV therapeutic vaccine - Abivax/CIGBHepatitis B vaccine - CIGB
Beyond the preview
Go deeper on NASVAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NASVAC.